Has This Teen Been Physically Abused?

For the answer, click here.

Question 2:

Polycystic ovary syndrome (PCOS) is the most common endocrinopathy among reproductive-aged women.

NEXT QUESTION »

For the answer, click here.

Question 3:

NEXT QUESTION »

For the answer, click here.

Question 4:

NEXT QUESTION »

For the answer, click here.

Question 5:

A 76-year-old man was referred for evaluation of chronic intermittent dysphagia for solid food. He had a history of rectal cancer that was diagnosed 8 years earlier. Endosonographic ultrasonography showed a thickened gastric wall of the cardia. Endoscopic mucosal resection was performed. Pathology results are shown.

ANSWER KEY »

Vertex Presents Phase 3 Data on Nonopioid Suzetrigine to Treat Acute Pain at Anesthesiologists' Annual Meeting

ANSWER KEY:

Question 1. B

Question 2. D

Question 3. G

Question 4. B

Question 5. C

Related Content

Suzetrigine Phase 3 Data Presented During "Best Abstract" Session at Anesthesiologists' Annual Meeting / image credit postop concept: ©Justlight AI/stock.adobe.com

October 21st 2024

Obesity & Pain Management: A Primary Viewpoints Podcast

The FDA has set a PDUFA date of January 30, 2025 for the investigational oral nonopioid therapy for acute pain, which could be a first-in-class win for Vertex.

April 27th 2023

Youth with Chronic Pain Face Greater Symptoms of Depression, Anxiety than Pain-Free Peers

In our latest episode, an obesity medicine physician explains the importance of a comprehensive plan to manage chronic pain in patients with obesity.

October 2nd 2024

Primary Viewpoints Episode 19: Mobile Health Technology for Chronic Pain Management

Findings from a systematic review and meta-analysis showed 1 in 3 youth with chronic pain were diagnosed with anxiety and 1 in 8 were diagnosed with depression.

September 29th 2022

FDA Accepts Vertex NDA for Suzetrigine, Investigational Oral Nonopioid Analgesic for Acute pain

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Lynn Webster, MD, past president of the American Academy of Pain Medicine.

August 15th 2024

Three Obesity-Related Comorbidities and Management Guidance for Primary Care

If approved the selective NaV1.8 pain signal inhibitor would reflect the first new class of pain management medication in more than 20 years.

July 17th 2024

Vertex Presents Phase 3 Data on Nonopioid Suzetrigine to Treat Acute Pain at Anesthesiologists' Annual Meeting

Get details on the relationship between obesity and mental health conditions, chronic pain, and hypertension, here.

Related Content

October 21st 2024

Obesity & Pain Management: A Primary Viewpoints Podcast

The FDA has set a PDUFA date of January 30, 2025 for the investigational oral nonopioid therapy for acute pain, which could be a first-in-class win for Vertex.

April 27th 2023

Youth with Chronic Pain Face Greater Symptoms of Depression, Anxiety than Pain-Free Peers

In our latest episode, an obesity medicine physician explains the importance of a comprehensive plan to manage chronic pain in patients with obesity.

October 2nd 2024

Primary Viewpoints Episode 19: Mobile Health Technology for Chronic Pain Management

Findings from a systematic review and meta-analysis showed 1 in 3 youth with chronic pain were diagnosed with anxiety and 1 in 8 were diagnosed with depression.

September 29th 2022

FDA Accepts Vertex NDA for Suzetrigine, Investigational Oral Nonopioid Analgesic for Acute pain

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Lynn Webster, MD, past president of the American Academy of Pain Medicine.

August 15th 2024

Three Obesity-Related Comorbidities and Management Guidance for Primary Care

If approved the selective NaV1.8 pain signal inhibitor would reflect the first new class of pain management medication in more than 20 years.

July 17th 2024